Tag: nasdaq:lxrx

Lexicon Pharmaceuticals Completes a Safety Review in TELE-ABC

The company has announced it has completed the safety of an initial run-in cohort of its TELE-ABC Phase 2 clinical...

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Lexicon Soars

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Paratek Up 41 Percent

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...

Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study

Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced the dosing of the first patient in the Telotristat Ethyl for Advanced Biliary Tract Cancer...

Pharma Outlook 2019: Drug Pricing Dialogue Continues

During this challenging time in healthcare news, our pharma outlook aims to help investors steer through the industry.

FDA Advisory Committee to Review Investigational Sotagliflozin as Potential Treatment for Type 1 Diabetes

Lexicon Pharmaceuticals (Nasdaq:LXRX), today announced that the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) plans...

Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides a Business Update

Lexicon Pharmaceuticals (NASDAQ:LXRX) has announced its financial results for the quarter ended June 30, 2018. As quoted in the press...